Current Headlines

91. C4XD And Horizon Discovery Enter Exclusive Partnership
    12/17/2018

    C4X Discovery Holdings plc, a pioneering drug discovery company, recently announces that it has entered into an exclusive target discovery partnership with Horizon Discovery Group plc (“Horizon”, AIM: HZD), a global leader in the application of gene editing and gene modulation technologies

92. FibroGen Announces Approval Of Roxadustat In China For The Treatment Of Anemia In Chronic Kidney Disease Patients On Dialysis
    12/17/2018

    FibroGen, Inc. (NASDAQ:FGEN) today announced that FibroGen (China) Medical Technology Development Co., Ltd. (FibroGen China) has received marketing authorization from the National Medical Products Administration (NMPA) for roxadustat, a first-in-class hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) for the treatment of patients with anemia caused by chronic kidney disease (CKD) in patients who are dialysis-dependent (DD)

93. Artificial Intelligence Is Propelling The Pharmaceutical Industry By Enabling Smart Drug Discovery Solutions
    12/17/2018

    With 97 percent of all drug discovery programs failing, the development of a single new therapeutic involves an average cost of $2.6 billion

94. Systems Oncology Announces Pipeline Of Innovative Drugs Emerging From The Use Of Artificial Intelligence
    12/14/2018

    Dr. Spyro Mousses, CEO of Systems Oncology, LLC, announced Systems Oncology’s diversified pipeline of innovative oncology programs discovered with the help of Artificial Intelligence at the AIMed North America Conference in Dana Point, California

95. Positioning High-Throughput CETSA In Early Drug Discovery Through Screening Against B-Raf And PARP1
    12/14/2018

    A new study published ahead-of-print by SLAS Discoverydescribes an evaluation of microplate-based high-throughput cellular thermal shift assay (CETSA HT) performed at AstraZeneca to assess its suitability and reliability for application to early drug discovery campaigns

96. New Therapeutic Area Leaders Extend PPD’s Drug Development Capabilities
    12/13/2018

    Pharmaceutical Product Development, LLC (PPD) is adding significant therapeutic expertise in cardiovascular disease, critical care, endocrinology, metabolism and diabetes to further broaden its global product development portfolio

97. Killing The Liver-Stage Malaria Parasite With Baculovirus: A Drug Discovery Approach
    12/12/2018

    Currently, few antimalarial treatments exist that effectively kill liver-stage malaria parasites, which can lay dormant for months or years as in the case of Plasmodium vivax

98. New 2-In-1 Powder Aerosol Medicine To Stop Deadly Superbugs In The Lungs
    12/12/2018

    Purdue University researchers have developed a new approach to treating the fourth-leading cause of death worldwide – lower respiratory infections

99. Generex Biotechnology Receives IND Approval From FDA For Phase II Combination Study Using AE37 Plus Keytruda (Pembrolizumab) For The Treatment Of Triple Negative Breast Cancer
    12/12/2018

    Generex Biotechnology Corporation recently announced that the FDA had reviewed the company’s investigational new drug (IND) application and given notification that the study can proceed

100. Almirall And X-Chem Announce Dermatology-Focused Drug Discovery Collaboration
     12/12/2018

     X-Chem, Inc. (X-Chem), a privately held biotechnology company applying its innovative drug discovery platform to the generation of novel small molecule therapeutics, announced recently a drug discovery partnership with Almirall, S.A. (Almirall) to discover lead compounds for innovative and challenging targets with dermatology applications